Global Fascioliasis Market Size, Trends, By Treatment (Triclabendazole, Nitazoxanide, Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), – Industry Trends and Forecast to 2030.
Global Fascioliasis Market
The global fascioliasis market was valued at USD 255.2 million in 2022 which expected to reach USD 502.6 million by 2030, at a CAGR 4.24% from 2023 to 2030.
Fascioliasis, usually referred to as a liver fluke infestation, is a neglected tropical disease subgroup characterized by parasitic flatworm infections brought on by fasciola hepatica. Fascioliasis typically manifests as eosinophilia, diarrhea, stomach pain, and feverish episodes that are irregular. Most people who are afflicted with this virus don't exhibit any symptoms, though occasionally biliary system problems may appear. Long-term issues can also arise in rare circumstances.
Market Drivers
Along with the WHO, the government has a number of supportive programs to raise awareness of treatments, subsidized medications, and reimbursement procedures. The government actively supports pharma makers that are striving to produce treatments for fascioliasis through funding aids and programs. This accelerates market expansion.
Furthermore, fascioliasis is a widespread disease, according to the Centers for Disease Control and Prevention (CDC). Additionally, animals are more likely than humans to get fascioliasis. Over two million people are expected to be infected globally. Additionally, 91 million people globally are at danger of contracting an infection, according to a study that was published in The American Journal of Tropical Medicine and Hygiene. This accelerates market expansion.
Moreover, clinical trials and medication development processes are expanding, which is opening up numerous chances for market expansion. For instance, the benzimidazole chemical triclabendazole is frequently used in veterinary medicine to treat fascioliasis. The WHO recommended adding triclabendazole to the list of essential medications in 1997 following a number of clinical trials utilizing the drug to treat fascioliasis. Therefore, the growth of the market depends on these aspects.
Market Restraints
The high cost of these agents undoubtedly inhibits market expansion. Although drug manufacturers are considering ways to make medications like triclabendazole more affordable. Additionally, following the WHO's suggestion, the development of safer and more effective drugs is currently underway. Examples include niclofolan emetine, chloroquine, and heptachlor-para-xylol.
Also, the market expansion is anticipated to be hampered by severe side effects related to medications used to treat fascioliasis. The market's expansion is hampered by side effects from nitazoxanide, such as nausea, stained urine, headaches, and stomachaches, followed by side effects from triclabendazole, such as excessive sweating, dizziness, nausea, hives, and itching.
Market Segmentation
The global fascioliasis market is segmented into treatment such as Triclabendazole, Nitazoxanide, and Others. By route of administration, the market is segmented into Oral, Parenteral, and Others. By end user, the market is segmented into Hospitals, Homecare, Specialty Clinics, and Others.
Regional Analysis
The major regions covered in the global fascioliasis market are North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Although fasciola hepatica infections in cattle and sheep are becoming more common in this region, North America is anticipated to account for a sizeable portion of the worldwide fascioliasis market. According to a report published in the American Journal of Tropical Medicine and Hygiene, many parts of the United States are affected by veterinary disease. California has a relatively high prevalence of Fasciola hepatica infection, particularly in sheep and cattle. In addition, according to the same source, 90% of mature cattle in the region's surrounding areas will have Fasciola hepatica infection.
Key Players
SeQuent, Shandong Octagon Chemicals Limited, AdvaCare Pharma, Novartis AG, Merck & Co., Zoetis Inc., Romark Laboratories L.C, Endo International Plc (Par Pharmaceutical), Elanco (Bayer AG), GlaxoSmithKline PLC, etc. 
Market Taxonomy 
By Treatment 
•        Triclabendazole
•        Nitazoxanide
•        Others
By Route of Administration
•        Oral
•        Parenteral
•        Others
By End Users
•        Hospitals
•        Homecare
•        Specialty Clinics
•        Others
By Region
•        North America (U.S. Canada, Mexico)
•        Latin America (Brazil, Rest of Latin America)
•        Europe (Germany, UK, Italy, France, Rest of Europe
•        Asia Pacific (China, India, Japan, Rest of Asia Pacific)
•        Middle East & Africa (Saudi Arabia, Kuwait, UAE, Egypt, South Africa)
 

Global Fascioliasis Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Fascioliasis Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Fascioliasis Market, By Treatment
5.1 Y-o-Y Growth Comparison, By Treatment
5.2 Global Fascioliasis Market Share Analysis, By Treatment
5.3 Global Fascioliasis Market Size and Forecast, By Treatment
5.3.1 Triclabendazole
5.3.2. Nitazoxanide
5.3.3. Others
6 Global Fascioliasis Market, By Route of Administration
6.1 Y-o-Y Growth Comparison, By Route of Administration
6.2 Global Fascioliasis Market Share Analysis, By Route of Administration
6.3 Global Fascioliasis Market Size and Forecast, By Route of Administration 
6.3.1 Oral
6.3.2 Parenteral
6.3.3. Others
7 Global Fascioliasis Market, By End User
7.1 Y-o-Y Growth Comparison, By End User
7.2 Global Fascioliasis Market Share Analysis, By End User
7.3 Global Fascioliasis Market Size and Forecast, By End User
7.3.1 Hospitals
7.3.2 Homecare
7.3.3. Specialty Clinics
7.3.4. Others
8 Global Fascioliasis Market, By Region
8.1 Global Fascioliasis Market Share Analysis, By Region
8.2 Global Fascioliasis Market Size and Forecast, By Region
8.3 Global Fascioliasis Market Trends and Forecast, By Region
9 North America Fascioliasis Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Fascioliasis Market Share Analysis, By Treatment
9.3 North America Fascioliasis Market Size and Forecast, By Route of Administration 
9.4 North America Fascioliasis Market Size and Forecast, By End User
9.5 North America Fascioliasis Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Fascioliasis Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Fascioliasis Market Share Analysis, By Treatment
10.3 Europe Fascioliasis Market Size and Forecast, By Route of Administration 
10.4 Europe Fascioliasis Market Size and Forecast, By End User
10.5 Europe Fascioliasis Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.5.4 Rest of Europe
11 Asia Pacific Fascioliasis Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Fascioliasis Market Share Analysis, By Treatment
11.3 Asia Pacific Fascioliasis Market Size and Forecast, By Route of Administration 
11.4 Asia Pacific Fascioliasis Market Size and Forecast, By End User
11.5 Asia Pacific Fascioliasis Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Rest of Asia
12 Latin America Fascioliasis Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Fascioliasis Market Share Analysis, By Treatment
12.3 Latin America Fascioliasis Market Size and Forecast, By Route of Administration 
12.4 Latin America Fascioliasis Market Size and Forecast, By End User
12.5 Latin America Fascioliasis Market Size and Forecast, By Country
12.5.1 Brazil
12.5.2 Rest of Latin America
13 Middle East Fascioliasis Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Fascioliasis Market Share Analysis, By Treatment
13.3 Middle East Fascioliasis Market Size and Forecast, By Route of Administration 
13.4 Middle East Fascioliasis Market Size and Forecast, By End User
13.5 Middle East Fascioliasis Market Size and Forecast, By Country
13.5.1. Saudi Arabia
13.5.2 UAE
13.5.3 Egypt
13.5.4 Kuwait
13.5.5 South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 SeQuent
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Shandong Octagon Chemicals Limited
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. AdvaCare Pharma
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Novartis AG
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Merck & Co
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Zoetis Inc
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Abbott
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Merck & Co., Inc
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Romark Laboratories L.C
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Endo International Plc (Par Pharmaceutical)
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
15.11 Elanco (Bayer AG)
15.11.1 Overview
15.11.2 Offerings
15.11.3 Key Financials
15.11.4 Business Segment & Geographic Overview
15.11.5 Key Market Developments
15.11.6 Key Strategies
15.12 GlaxoSmithKline PLC
15.12.1 Overview
15.12.2 Offerings
15.12.3 Key Financials
15.12.4 Business Segment & Geographic Overview
15.12.5 Key Market Developments
15.12.6 Key Strategies
15.13.6 Key Strategies